NUCANA PLC-ADR (NCNA) Stock Price & Overview

NASDAQ:NCNA • US67022C3043

Current stock price

1.64 USD
-0.07 (-4.09%)
Last:

The current stock price of NCNA is 1.64 USD. Today NCNA is down by -4.09%. In the past month the price decreased by -20.28%. In the past year, price decreased by -99.99%.

NCNA Key Statistics

52-Week Range1.63 - 53600
Current NCNA stock price positioned within its 52-week range.
1-Month Range1.63 - 2.27
Current NCNA stock price positioned within its 1-month range.
Market Cap
625.85M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-68.08
Dividend Yield
N/A

NCNA Stock Performance

Today
-4.09%
1 Week
-14.07%
1 Month
-20.28%
3 Months
-51.97%
Longer-term
6 Months -53.66%
1 Year -99.99%
2 Years -100.00%
3 Years -100.00%
5 Years -100.00%
10 Years N/A

NCNA Stock Chart

NUCANA PLC-ADR / NCNA Daily stock chart

NCNA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to NCNA. When comparing the yearly performance of all stocks, NCNA is a bad performer in the overall market: 98.56% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NCNA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NCNA. The financial health of NCNA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NCNA Earnings

Next Earnings DateJun 1, 2026
Last Earnings DateMar 18, 2026
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

NCNA Forecast & Estimates


Analysts
Analysts82.5
Price TargetN/A
EPS Next Y34%
Revenue Next YearN/A

NCNA Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

NCNA Financial Highlights

Over the last trailing twelve months NCNA reported a non-GAAP Earnings per Share(EPS) of -68.08. The EPS increased by 99.87% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-27.52M
Industry RankSector Rank
PM (TTM) N/A
ROA -85.16%
ROE -106.15%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%100%
Sales Q2Q%N/A
EPS 1Y (TTM)99.87%
Revenue 1Y (TTM)N/A

NCNA Ownership

Ownership
Inst Owners2.51%
Shares381.62M
Float381.62M
Ins Owners0%
Short Float %0.05%
Short Ratio2.82

About NCNA

Company Profile

NCNA logo image NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

Company Info

IPO: 2017-09-28

NUCANA PLC-ADR

Lochside House, 3 Lochside Way

Edinburgh EH12 9DT GB

CEO: Hugh Griffith

Employees: 20

NCNA Company Website

NCNA Investor Relations

Phone: 4401313571111

NUCANA PLC-ADR / NCNA FAQ

What does NUCANA PLC-ADR do?

NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.


What is the stock price of NUCANA PLC-ADR today?

The current stock price of NCNA is 1.64 USD. The price decreased by -4.09% in the last trading session.


What is the dividend status of NUCANA PLC-ADR?

NCNA does not pay a dividend.


How is the ChartMill rating for NUCANA PLC-ADR?

NCNA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the PE ratio for NCNA stock?

NUCANA PLC-ADR (NCNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-68.08).


How many employees does NUCANA PLC-ADR have?

NUCANA PLC-ADR (NCNA) currently has 20 employees.